SELLAS Life Sciences Group, Inc. Business Acquisition, Pro Forma Net Income (Loss)
SELLAS Life Sciences Group, Inc. (SLS) reported Business Acquisition, Pro Forma Net Income (Loss) of -$24.09 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2019-03-22
- SELLAS Life Sciences Group, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2017-12-31 was -$2.40M.
- SELLAS Life Sciences Group, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2017-09-30 was -$9.07M.
- SELLAS Life Sciences Group, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2017-06-30 was -$12.57M.
- SELLAS Life Sciences Group, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2017-03-31 was -$6.75M.
- SELLAS Life Sciences Group, Inc. business acquisition, pro forma net income (loss) for fiscal 2017 was -$24.09M, a 184.85% decline from fiscal 2016.
- SELLAS Life Sciences Group, Inc. business acquisition, pro forma net income (loss) for fiscal 2016 was $28.39M.
- SELLAS Life Sciences Group, Inc. business acquisition, pro forma net income (loss) for fiscal 2011 was -$4.70M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2017-12-31 | -$2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | -$11.46M derived: sum of 2 quarters · filed 2019-03-22 | -$24.03M derived: sum of 3 quarters · filed 2019-03-22 | -$24.09M 10-K · filed 2019-03-22 | $24.09M 10-K · filed 2018-04-13 |
| 2017-09-30 | -$9.07M 10-Q · filed 2018-11-14 | -$21.63M derived: sum of 2 quarters · filed 2018-11-14 | -$21.69M 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | -$12.57M 10-Q · filed 2018-08-14 | -$21.57M 10-Q · filed 2018-08-14 | |||
| 2017-03-31 | -$6.75M 10-Q · filed 2018-05-15 | ||||
| 2016-12-31 | $28.39M 10-K · filed 2018-04-13 | ||||
| 2011-12-31 | $3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | -$361.00K derived: sum of 2 quarters · filed 2014-03-17 | -$2.40M derived: sum of 3 quarters · filed 2014-03-17 | -$4.70M 10-K · filed 2014-03-17 | |
| 2011-09-30 | -$4.19M 10-Q · filed 2012-11-13 | -$6.23M derived: sum of 2 quarters · filed 2012-11-13 | -$8.53M 10-Q · filed 2012-11-13 | ||
| 2011-06-30 | -$2.04M 10-Q · filed 2012-08-14 | -$4.34M 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |